menu
    • menu
    [{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"WuXi AppTec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"ST-067","moa":"IL-18","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Simcha Therapeutics \/ WuXi AppTec","highestDevelopmentStatusID":"7","companyTruncated":"Simcha Therapeutics \/ WuXi AppTec"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"DR-18","moa":"Il-18","graph1":"Oncology","graph2":"Preclinical","graph3":"Simcha Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Simcha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Simcha Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Series B Financing","leadProduct":"ST-067","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Simcha Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"7","companyTruncated":"Simcha Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"ST-067","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Simcha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Simcha Therapeutics \/ Merck & Co. Inc.","highestDevelopmentStatusID":"7","companyTruncated":"Simcha Therapeutics \/ Merck & Co. Inc."},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"CAR T-based Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Simcha Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Simcha Therapeutics \/ Janssen Biotech","highestDevelopmentStatusID":"4","companyTruncated":"Simcha Therapeutics \/ Janssen Biotech"},{"orgOrder":0,"company":"Simcha Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Vevoctadekin","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Simcha Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Simcha Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Simcha Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Simcha Therapeutics

    Menu

    Simcha Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Simcha Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Simcha Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vevoctadekin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Simcha Starts Studies Of ST-067 in Hematological Disorders

                            Details : ST-067 (vevoctadekin) is a decoy-resistant interleukin-18 stimulator, which is currently being evaluated for the treatment of patients with acute myeloid leukemia.

                            Product Name : Undisclosed

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 05, 2024

                            Lead Product(s) : Vevoctadekin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Simcha Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Simcha Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CAR T-based Cell Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : JANSSEN BIOTECH

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Simcha Therapeutics Licenses Decoy-Resistant IL-18 for Cell Therapy

                            Details : Under the terms of the agreement, Janssen will develop, manufacture, and commercialize CAR T-based cell therapy candidates with Simcha’s novel proprietary DR-18 for a set number of programs.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 08, 2024

                            Lead Product(s) : CAR T-based Cell Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : JANSSEN BIOTECH

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Simcha Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Simcha Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ST-067,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Simcha Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ST-067 in Combination with K...

                            Details : The collaboration aims to evaluate clinical safety and benefits of ST-067, Simcha’s decoy resistant IL-18 agent, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with solid tumors.

                            Product Name : ST-067

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 05, 2023

                            Lead Product(s) : ST-067,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Simcha Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Simcha Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ST-067

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BVF Partners

                            Deal Size : $40.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Simcha Therapeutics Raises $40 Million Series B Financing and Initiates Phase 1/2 Study to Evaluate Novel Inte...

                            Details : In addition, the Company has dosed the first patient in the Phase 1 portion of a first-in human multi-center Phase 1/2 clinical trial of its first drug candidate ST-067, a first-in-class “decoy-resistant” Interleukin-18 variant.

                            Product Name : ST-067

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 27, 2022

                            Lead Product(s) : ST-067

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BVF Partners

                            Deal Size : $40.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Simcha Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Simcha Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ST-067

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : WuXi AppTec

                            Deal Size : $25.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Simcha debuts with $25M to advance custom-built IL-18 for cancer

                            Details : Simcha’s lead program involves a customized variant of interleukin-18 (IL-18), a cytokine with potent antitumor effects, developed in the lab of Scientific Founder Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology at the Yale School of Medi...

                            Product Name : ST-067

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 24, 2020

                            Lead Product(s) : ST-067

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : WuXi AppTec

                            Deal Size : $25.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Simcha Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed

                            Simcha Therapeutics

                            U.S.A arrow
                            PharmScience R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DR-18

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Simcha Therapeutics Shares Data at AACR Annual Meeting Highlighting Potent Preclinical Efficacy of Decoy-Resis...

                            Details : Oral presentation and poster detail DR-18’s ability to re-animate exhausted NK cells, bias differentiation of T cells toward highly active effectors and expand the population of critical immune cells inside the tumor microenvironment.

                            Product Name : DR-18

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 24, 2020

                            Lead Product(s) : DR-18

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth